Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04504032 · ClinicalTrials.gov registry record · Phase 2
A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)
A Phase 2 study, sponsored by Gates Medical Research Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 497
- Enrollment target
NCT04504032: Clinical Trial Phase 2 study, sponsored by Gates Medical Research Institute.
NCT04504032 is a Phase 2 study that was terminated before completion, run by Gates Medical Research Institute. The registered enrollment target is 497 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (274% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04504032, a Phase 2 study, was terminated before completion, sponsored by Gates Medical Research Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 497 participants
- Enrollment target
Study Summary
The purpose of this study is to assess safety and clinical efficacy of rivaroxaban in people with mild Coronavirus Disease 2019 who are at increased risk of disease progression.
Primary Outcome
An AE is any untoward medical occurrence that occurs in a participant. An AE can be any unfavorable and unintended sign (including abnormal laboratory findings), symptom, or disease temporally associated with treatment, whether considered related to the product. AEs may include the onset of a new illness or undesirable medical condition or the exacerbation of pre-existing medical conditions. AE severity was graded as Grade 3 (Severe) and Grade 4 (Potentially Life-threatening) per the specific to
Interventions
- DRUG Placebo
- DRUG Rivaroxaban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 497 participants |
| Start Date | 2020-09-02 |
| Est. Completion | 2021-03-29 |
| Phase | Phase 2 |
Why NCT04504032 stopped before completion
NCT04504032 is an interventional study that assigns participants to a tested intervention. The registered 497 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (274% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04504032 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04504032 about?
NCT04504032 is a clinical study titled "A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)". The purpose of this study is to assess safety and clinical efficacy of rivaroxaban in people with mild Coronavirus Disease 2019 who are at increased risk of disease progression.
What is the current status of trial NCT04504032?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 497 participants. The study started on 2020-09-02. Estimated completion is 2021-03-29.
What interventions are being tested in trial NCT04504032?
The interventions under investigation include: Placebo (DRUG), Rivaroxaban (DRUG).
Who is sponsoring clinical trial NCT04504032?
This trial is sponsored by Gates Medical Research Institute, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04504032's enrollment target sits among peer trials
497 74th of 2000 higher than 1,926 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03175224 · 497 participants · Phase 2
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
- NCT05301816 · 497 participants · NA
PDN Post Market, Multicenter, Prospective, Global Clinical Study
- NCT05766670 · 497 participants · Phase 3
Intramedullary Calcium Sulfate Antibiotic Depot
- NCT05283720 · 496 participants · Phase 2
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI